Empleos actuales relacionados con AI-Driven Oncology Drug Discovery Scientist - barcelona - Gordion
-
AI-Driven Oncology Drug Discovery Scientist
hace 1 semana
Barcelona, España Gordion A tiempo completoOverviewMaximice sus posibilidades de que su candidatura sea seleccionada asegurándose de que su CV y sus habilidades se ajustan al perfil.MOTIVATED TO MAKE BETTER DRUGS -POWERED WITH TUMOR DATA -DELIVERED BY MACHINE LEARNINGToday is one of those goose‑bump moments at Gordion Bioscience !We’ve officially licensed out our MTAP‑deleted‑tumour...
-
Barcelona, España Johnson & Johnson A tiempo completoA leading healthcare innovation firm is recruiting a Senior Scientist for AI Agent Systems in Drug Discovery in Barcelona, Spain. This hybrid role involves developing AI-driven solutions that improve drug discovery and development processes. Candidates should have a Ph.D. in AI/ML and a strong background in relevant mathematics and programming....
-
Barcelona, España Johnson & Johnson A tiempo completoAt Johnson & Johnsonwe believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented treated and curedwhere treatments are smarter and less invasive andsolutions are our expertise in Innovative Medicine and MedTech we are uniquely positioned to innovate across the full spectrum of...
-
Senior Director, Translational Medicine, Oncology
hace 1 semana
Barcelona, España AstraZeneca A tiempo completoWe are seeking a Senior Director in Oncology Translational Medicine to join a world class center for discovery and development of innovative cancer medicines. In this role you will be accountable for leading a team for delivery of robust, scientifically-driven biomarkers in drug discovery and development programs for a portfolio of targeted agents across our...
-
Senior Scientist Oncology Data Science and Ai
hace 2 semanas
Barcelona, España AstraZeneca A tiempo completoAre you ready to redefine cancer treatment and restore patients' lives? At AstraZeneca, a global science-driven biopharmaceutical company, we are committed to discovering and delivering innovative medicines that enrich lives. Our Early Data Science team within the Oncology Data Science and AI group is expanding to tackle the challenges of pre-clinical and...
-
Director, Translational Medicine, Oncology
hace 1 semana
Barcelona, España AstraZeneca A tiempo completoLocation: Barcelona (On-site) At **AstraZeneca**, we work together across global boundaries to make an impact and find answers to challenges. We do this with the utmost integrity even in the most difficult situations because we are committed to doing the right thing. We continuously forge partnerships that help pursue world-class medicines in new ways,...
-
Barcelona, España AstraZeneca A tiempo completoDirector, Principal Patient Safety Scientist OncologyBarcelona, Spain (on-site) 3 days working from the office and 2 days working from home. AstraZeneca is a global, science‑led, patient‑focused biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines for some of the world’s most serious...
-
Global Development Scientist Director, Late Oncology
hace 2 semanas
Barcelona, España AstraZeneca A tiempo completo**Loction: Barcelona (On-site)** We are looking to hire a Global Development Scientist Director Late Oncology. Do you have expertise in, and passion for clinical drug development? Are you looking to work at the cutting-edge, where scientific innovations and an entrepreneurial spirit are the norm? Join the team at the heart of AstraZeneca dedicated to...
-
Barcelona, España AstraZeneca A tiempo completoDo you have expertise in, and passion for clinical drug development? Are you looking to work at the cutting-edge, where scientific innovations and an entrepreneurial spirit are the norm? Join the team at the heart of AstraZeneca dedicated to Oncology, committed to following the science. **About AstraZeneca** AstraZeneca is a global, science-led,...
-
Director, Translational Medicine, Oncology
hace 2 semanas
Barcelona, España AstraZeneca A tiempo completo**Position: Director, Translational Medicine, Oncology - Breast cancer** **Location: Cambridge, UK or Boston, US** At **AstraZeneca**, we work together across global boundaries to make an impact and find answers to challenges. We do this with the utmost integrity even in the most difficult situations because we are committed to doing the right thing. We...
AI-Driven Oncology Drug Discovery Scientist
hace 3 semanas
Overview MOTIVATED TO MAKE BETTER DRUGS -POWERED WITH TUMOR DATA -DELIVERED BY MACHINE LEARNING Today is one of those goose‑bump moments at Gordion Bioscience We’ve officially licensed out our MTAP‑deleted‑tumour programme to the brilliant minds at Kohde Pharma .This licensing deal proves and underscores our firm believe that patient data+AI outshine cell‑line models. Why? Because our platform can uncover cancer vulnerabilities that just aren’t visible in cell lines. This opens the doors to uncovering entirely new targets and, ultimately, better treatment outcomes. Why this milestone matters: MTAP deletions appear in ~15% of all cancers, yet patients still lack targeted options. Kohde Pharma has full access to Gordion’s AI‑powered platform. Gordion mined real patient data and uncovered new synthetic‑lethal targets. Huge congratulations to Thomas Wirth , Pawel Zawadzki , and the entire teams at Kohde Pharma and Gordion Bioscience for making this happen One program licensed. Many more to come. The future of drug discovery is data‑native, AI enabled, patient‑powered and boldly collaborative. #DrugDiscovery #MTAP #OncologyInnovation #DataDrivenScience #AIDrugDiscovery #PrecisionMedicine #Collaboration #TeamingUpForPatients Leadership and Team Updates Welcome Thomas Wirth to Gordion Bioscience as our Interim Chief Business OfficerCould there be better news than having Thomas join us to help shape the future with his expertise, leadership, and vision? With over 20 years in biotech, Thomas has been instrumental in bringing groundbreaking science to the clinic—leading Phase I trials, securing major investments, and driving innovation in oncology and regenerative medicine. His experience spans early-stage venture development, strategic growth, and navigating complex regulatory landscapes.Thomas has held key leadership roles, including Chief Business Officer at Nodus Oncology, Strategic Advisor at GIO Therapeutics, and Executive in Residence at Cumulus Oncology, where he scouted oncology investment opportunities and drove fundraising initiatives. As the founder of Aurealis Therapeutics, he built a novel gene and cell therapy platform, secured major industry partnerships, and played a pivotal role in advancing innovative treatments. It’s so good to have you on board, Thomas #Oncology #Teamwork #Collaboration #DrugDevelopment #MakingAnImpact CEO at Gordion Bio, pioneering patient-derived drug program designs Industry Perspective Another reason why DeepSeek is such a 'Sputnik moment'—not just for AI but also for drug discovery—is that it demonstrated a systemic approach to engineering breakthroughs by questioning key assumptions one by one (e.g., do you need so much data and compute?). Ask your startup: what underlying principle or belief—has your team chosen to challenge? Questioning these foundational assumptions is what separates teams engineering breakthroughs from those relying on luck. At Gordion, we’ve embraced this principle to build our model. Two years ago, most people told us it was impossible to create a cancer genomics model for novel target identification using 10,000 datasets, each with 3.2 billion variables. By challenging this assumption and applying the approach described by Jon Turow below, we’ve developed a model capable of identifying novel drug targets invisible to other methods. Jon Turow Builder. Madrona Partner. Ex Amazon AWS. 7mo DeepSeek R1's performance and cost numbers have the industry's attention, but its approach to model building might be the bigger breakthrough. Yes, it's a gift to app developers who get powerful new open-source models to build on. And yes, major labs will use these efficiency innovations to build even bigger models.But there's a deeper story here: DeepSeek shows how domain expertise might matter more than raw compute in building specialized AI models. Their approach - using verifiable data and efficient reward functions - creates a new path for teams with deep domain knowledge to build their own models at a fraction of the usual cost.Consider that DeepSeek emerged from a hedge fund, where the reward function is crystal clear. This hints at how other domain experts might leverage similar techniques - whether in finance, medicine, law, or industrial operations.We're entering an era where smart training may matter more than raw compute. The future of AI may not just belong to those with the biggest GPU clusters, but to those who can most effectively combine domain expertise with clever training techniques.I explore this shift in depth here: Statements from Leadership CEO at Gordion Bio, pioneering patient-derived drug program designs Pawel Zawadzki CEO at Gordion Bio, pioneering patient-derived drug program designs Upcoming Activities 10mo Edited Excited to be back at BIO-Europe Looking forward to talking about In-Patient CRISPR screening for novel target ID. Incredible to be here at the 36th EORTC-NCI-AACR Symposium in Barcelona, surrounded by so many brilliant minds advancing cancer research and drug development It’s inspiring to engage in meaningful discussions, gain insights, and observe the latest innovations in oncology.Being part of this vibrant community reinforces our commitment Gordion Bioscience to integrating real patient tumor data into drug development, helping improve trial success and drive impactful treatments. Thank you to everyone who has shared their expertise and vision with us so far—we’re excited to see what’s nextIf you’re here, come say hello to Pawel Zawadzki and the team #ENA2024 #CancerResearch #OncologyInnovation Find people you know at Gordion Bioscience #J-18808-Ljbffr
